Altamira Therapeutics Ltd. CYTO
At closeFeb 10, 2026, 4:00 PM EST
52-week range unavailable
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 1.13M
- Shares out
- 3.78M
- Forward P/E
- -0.22
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 724.29K
- Open
- 0.30
- Previous close
- 0.30
- Day's range
- 0.30 – 0.30
- Beta
- 2.44
- Price target
- 5.01 (+1570.0%)
- Earnings date
- Jul 10, 2024
Key statistics
- Enterprise value
- 1.16M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.41M
- Total cash
- 65.45K
- Total debt
- 427.44K
- Return on equity
- -368.78%
- Short % of float
- 1.35%
- 50-day average
- 0.47474
- 200-day average
- 1.09
Analyst view
Next earnings
Jul 10, 2024
Expected Jul 10, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 10, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Bermuda
- Website
- altamiratherapeutics.com
News
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now 
Altamira Therapeutics Provides Update on Nasdaq Listing 
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray 
Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript 
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results 
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering 
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
Your note
Sign in to keep a note on CYTO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 2.98% | 101,444 | 30.43K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.44% | 14,802 | 4.44K | Sep 29, 2024 |
| Group One Trading, L.P. | 0.00% | 14 | 4 | Sep 29, 2024 |
| Lri Investments, LLC | 0.00% | 1 | 0 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.07% | 2,262 | 678 | Oct 30, 2024 |